Cushman & Wakefield Announces Pricing of its Initial Public Offering of Ordinary Shares
Cushman & Wakefield plc (“Cushman & Wakefield”) today announced the pricing of its initial public offering of 45,000,000 of its ordinary shares, at a price to the public of $17.00 per share. The shares will be listed on the New York Stock Exchange and will trade under the symbol “CWK” beginning August 2, 2018. In addition, Cushman & Wakefield has granted the underwriters a 30-day option to purchase up to an additional 6,750,000 ordinary shares at the public offering price less underwriting discounts and commissions.
Cushman & Wakefield expects to use the net proceeds from the ordinary shares offered by it to reduce outstanding indebtedness, in particular to repay its second lien loan, to pay the outstanding amount of the deferred payment obligation related to its acquisition of Cassidy Turley and any remaining net proceeds for general corporate purposes.
Morgan Stanley, J.P. Morgan, Goldman Sachs & Co. LLC and UBS Investment Bank are acting as joint book-running managers and representatives of the underwriters for the offering. Barclays Capital Inc., BofA Merrill Lynch, Citigroup Global Markets Inc., Credit Suisse Securities (USA) LLC and William Blair & Company, L.L.C. are also acting as joint book-running managers for the offering. TPG Capital BD, LLC, HSBC Securities (USA) Inc., Credit Agricole Securities (USA) Inc., JMP Securities LLC, China Renaissance Securities (US) Inc., Fifth Third Securities, Inc., Academy Securities, Inc., Loop Capital Markets LLC, Samuel A. Ramirez & Company, Inc., Siebert Cisneros Shank & Co. L.L.C. and The Williams Capital Group, L.P. are acting as co-managers for the offering.
The offering is being made only by means of the written prospectus forming part of the effective registration statement. Copies of the final prospectus related to the offering, when available, may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, email: firstname.lastname@example.org, Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: (866) 471-2526 or email: email@example.com and UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019, telephone: 888-827-7275 or email: firstname.lastname@example.org.
A registration statement relating to these securities was declared effective as of August 1, 2018 by the Securities and Exchange Commission. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, sale or solicitation would be unlawful prior to registration or qualification under the securities law in any such state or jurisdiction.
About Cushman & Wakefield
Cushman & Wakefield is a leading global real estate services firm that delivers exceptional value by putting ideas into action for real estate occupiers and owners. Cushman & Wakefield is among the largest real estate services firms with 48,000 employees in approximately 400 offices and 70 countries. In 2017, the firm had revenue of $6.9 billion across core services of property, facilities and project management, leasing, capital markets, valuation and other services.
Cautionary Note Regarding Forward-Looking Statements
Any statements in this release that are not historical or current facts are forward-looking statements. Forward-looking statements convey Cushman & Wakefield’s current expectations or forecasts of future events. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Cushman & Wakefield’s actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Certain of these risks and uncertainties are described in the “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” section of the Registration Statement on Form S-1. Unless required by law, Cushman & Wakefield undertakes no obligation to publicly update or revise any forward-looking statements to reflect circumstances or events after the date of this press release.
Cushman & Wakefield
+1 312 424 8010
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Veristat Congratulates Agios Pharmaceuticals on the FDA Approval of TIBSOVO®20.8.2018 11:00 | Tiedote
Veristat, a full service Clinical Research Organization (CRO), congratulates Agios on the recent FDA approval of TIBSOVO® (ivosidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA approved test. TIBSOVO®, an oral, targeted inhibitor of the IDH1 enzyme, is the first and only FDA-approved therapy for patients with R/R AML and an IDH1 mutation. Veristat is honored to have supported Agios with the preparation of the New Drug Application (NDA) for ivosidenib. We congratulate Agios on the approval of this ground-breaking therapy for patients with this life-threatening malignancy. Veristat began working with Agios on this compound five years ago, providing statistical and medical writing support for their phase I study for ivosidenib which led to the recent approval. Veristat’s support continued through the preparation of the NDA submission. “Over the last fi
Veristat is Recognized on the Inc. 5000 List of America’s Fastest-Growing Private Companies for the 4th Consecutive Year20.8.2018 11:00 | Tiedote
Veristat, a full service Clinical Research Organization (CRO), proudly announces its recognition once again by Inc. Magazine as one of the 5000 fastest-growing private companies in the United States. Since its first appearance on the list in 2015, Veristat has accelerated its growth in size, geographic reach and ability to successfully guide clinical trials through the development process to regulatory approval. “Veristat’s ability to achieve this national recognition and to remain on this list for 4 consecutive years highlights our sustainability, innovation and unfaltering commitment to consistently delivering the highest quality clinical development and regulatory submission services to our clients,” stated Patrick Flanagan, Chief Executive Officer at Veristat. “The meaningful impact that our teams provide to our clients and to lives of the patients their programs benefit is astounding. In 2018, our teams supported five regulatory submissions that were submitted to the US Food & Dru
Boehringer Ingelheim: New sub-analyses to be presented at ESC Congress 2018 further support positive safety profile of Pradaxa® (dabigatran etexilate)20.8.2018 10:00 | Tiedote
Boehringer Ingelheim today announced that it will present nine sub-analyses from the RE-DUAL PCITM trial and GLORIATM-AF Registry Program at the upcoming ESC Congress 2018, organised by the European Society of Cardiology, taking place in Munich, Germany on the 25-29 August 2018. The primary data from these studies have contributed to a positive label update for dabigatran etexilate (Pradaxa®) in the European Union (EU). The primary RE-DUAL PCITM trial investigated anticoagulation in patients with non-valvular atrial fibrillation (AF) following percutaneous coronary intervention (PCI) and stent placement. Data showed significantly lower rates of major or clinically relevant non-major bleeding events for dual therapy with dabigatran etexilate when compared to triple therapy with warfarin without compromise on efficacy.1,2 GLORIATM-AF is a large, prospective, observational study program run in over 40 countries worldwide. The primary analysis of nearly 5000 AF patients treated with dabiga
Alipay Launches World’s First Paperless Tax Refund Service in South Korea20.8.2018 06:24 | Tiedote
Alipay, the world’s leading mobile payment and lifestyle platform operated by Ant Financial Services Group, announced that it has partnered with Global Tax Free (“GTF”), a tax refund agency, to launch the world’s first paperless mobile tax refund function in South Korea. Alipay has consistently been at the forefront of innovation that supports mobile tax refund solutions globally. In early 2017, Alipay initiated a real-time tax refund service in Europe which enabled users to instantly receive tax rebates in their Alipay accounts after scanning their Alipay QR code at airport tax counters. The newly introduced tax refund service in South Korea further simplifies the process by enabling Chinese tourists to apply for and claim tax rebates on their mobile phone app, skipping in-city and airport tax refund counters altogether. After scanning their passports at self-service kiosks prior to leaving South Korea, Chinese tourists can process tax rebates and immediately receive RMB refunds by us
Manchester United Shoots for Success with a “Digital Experience Platform” Powered by HCL16.8.2018 22:02 | Tiedote
Manchester United (NYSE:MANU) has today announced a major milestone on its digital transformation journey with HCL Technologies, with the successful launch of the Manchester United Official app powered by HCL’s digital experience platform. The launch is part of the ongoing digital transformation of the club to provide a real-time, engaging, personalized, and unified experience to Manchester United’s 659 million global followers, which supports the club’s strategy to become a Digital Sports Enterprise. At the heart of this transformation is the digital platform developed by HCL, providing the club with a single view of fans across web and app touchpoints, offering fans a one-stop shop for everything Manchester United. Manchester United’s Group Managing Director Richard Arnold comments: “This app will allow our 659 million Manchester United followers to easily connect to the club they love, wherever they are in the world. Fans will now have the opportunity to follow all Manchester United
4K 4Charity Fun Run Announces Open Registration for IBC201816.8.2018 20:41 | Tiedote
AWS Elemental, an Amazon Web Services (AWS) company, today announced that the fifth annual 4K 4Charity Fun Run at IBC Show will take place at 7:00 a.m. local time on Saturday, Sept. 15 at Amstelpark in Amsterdam. Registration is open at https://4k4charity.com/ibc. Among the non-profits supported by the 4K 4Charity Fun Run at IBC Show is Amsterdam-based StichtingNewTechKids, which provides computer science education for girls, minorities, and economically challenged youth in the Netherlands. The organization supports a computer science teacher training program for primary school teachers with proceeds from 4K 4Charity. Also supported is Iridescent, a global education non-profit that empowers underrepresented young people to become innovators and leaders through engineering and technology. Through their two programs, Curiosity Machine AI Family Challenge and Technovation, Iridescent introduces underserved communities to new technologies and empowers and equips them to apply those technol
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme